Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1824893 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $19.40Day −2.07%Mkt cap $225M1Y +108.4%Off 52W high −44.6%Vol (1Y) 75.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,238 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.4% of sh out |
| Days to cover6.2d |
| 13F net flow (QoQ)+6.56% |
| Top-10 13F concentration69.9% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$7.5M |
| Earnings (TTM)-$342.6M |
| Net margin−6960.8% |
| Sales growth 3Y−34.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−14.2% |
| 1Y+108.4% |
| 3Y+60.9% |
| Since incept. (ann.)−32.7% |
Total return through 2026-07-28 · series begins 2021-08-13. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)75.6% |
| Ann. volatility (3Y)88.2% |
| Sharpe (1Y)1.37 |
| Sharpe (3Y)0.63 |
| Max drawdown (1Y)−43.2% |
| Max drawdown (3Y)−62.7% |
| Beta (3Y vs SPY)1.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 1.5M | $43M | 12.69% | new |
| Kalehua Capital Management LLC | 770,356 | $22M | 6.64% | +100.0% |
| Boxer Capital Management, LLC | 766,318 | $22M | 6.60% | +84.1% |
| MILLENNIUM MANAGEMENT LLC | 731,138 | $21M | 6.30% | +1.4% |
| STEMPOINT CAPITAL LP | 721,620 | $19M | 6.22% | +16.4% |
| Venrock Adviser, LLC | 632,931 | $18M | 5.45% | +0.0% |
| Spruce Street Capital LP | 432,040 | $13M | 3.72% | +0.0% |
| BRAIDWELL LP | 396,100 | $12M | 3.41% | −15.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$11.65 | — | $5.0M | +408.6% |
| 2025-12-31 | 2026-03-23 | — | — | $528,000 | −19.4% |
| 2025-09-30 | 2025-11-07 | −$8.36 | — | $983,000 | −90.2% |
| 2025-06-30 | 2025-08-08 | $2.55 | — | $983,000 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Research Service Revenue 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
